QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.
about
Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug developmentDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsA canine model of torsades de pointesQuinidine-induced paroxysmal ventricular fibrillation treated with propranololSotalol, hypokalaemia, syncope, and torsade de pointesTorsades de pointes, a common arrhythmia, induced by medicationToxicologic myocardial sensitization.Torsades de pointes: prevention and therapy.Drug-induced long QT syndrome in women.Cardiac syncope: a case exhibiting dichotomy between clinical impression and electrophysiologic evaluation.Inducible polymorphous ventricular tachycardia following Mustard operation for transposition of the great arteries.Effects of quinidine and disopyramide on serum digoxin concentrations.The case for inpatient initiation of antiarrhythmic therapy.Facts, fancies and follies of drug-induced QT/QTc interval shortening.Early and late proarrhythmia from antiarrhythmic drug therapy.Drug-induced long QT syndromeMaintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.Cellular basis of drug-induced torsades de pointesInotropic actions of lignocaine and phenytoin.Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.Antazoline therapy of recurrent refractory supraventricular arrhythmias--a preliminary report.Conversion of atrial fibrillation and flutter by propranolol.Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes.Long QT syndrome: reduced repolarization reserve and the genetic link.Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.Magnesium therapy in ventricular arrhythmias.Ventricular arrhythmias: risk stratification and approach to therapy after the Cardiac Arrhythmia Suppression Trial (CAST).Iatrogenic 'torsade de pointes' ventricular tachycardia.A critical reconsideration of the clinical effects and treatment recommendations for sodium channel blocking drug cardiotoxicity.Comparison of lidoflazine and quindine in prophylactic treatment of arrhythmias.Antiarrhythmic drug therapy in congestive heart failure. Indications and complications.Maintenance of sinus rhythm after DC reversion of atrial fibrilllation. A double-blind controlled trial of long-acting quinidine bisulphate.Appraisal of electroconversion in treatment of cardiac dysrhythmias.Electrical reversion of cardiac arrhythmiasProarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.Effect of quinidine on the digoxin receptor in vitroOn the relationship among QT interval, atrial fibrillation, and torsade de pointes.Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.
P2860
Q24646866-3E3575EF-EF54-483F-B5FF-A4A278C5D9D3Q28071256-1FFF267E-3075-4ACB-9288-26389776FF73Q28339450-051DFF05-0116-4649-8A4F-54BA4CE8D71FQ28365580-862F0583-AD62-4664-BFA1-C25F4109ACE5Q28365910-4A425751-240F-4327-81AF-FFC835ADEE3AQ28367864-BD3AA517-D09B-4FA5-991B-6AF1E19FC7C3Q33148458-15CB3D6C-DD55-48D1-B0C7-315956981D39Q33156343-55B08916-A11C-4234-9230-37E9F03E2478Q33163340-12EDF8A7-8F42-4CDA-8B25-67260F176951Q33163497-09A49DDD-E265-4FD0-8874-5409857F66BBQ33172233-BE1B6920-2634-4A81-BE08-069E4C131DCFQ33173016-2AC96F4D-76C2-4D79-BA2A-ABCE18BEF98CQ33598024-331C4FD7-AB62-4748-B9D4-A82E984F4321Q33661036-88B5F0F4-272C-4E49-A1C1-58290399C0EDQ34344018-B4FCF689-9575-4AAF-89C7-61690C40CB3EQ34358104-966EEB15-2F2E-431B-9C71-24E7C624DA54Q34778156-CDD071BE-C72A-4BDA-99BF-7A68DF70C701Q34786459-C6A2132B-9B2E-4310-A9BD-DA349E658E60Q35174038-8FCAAEE4-D505-465C-8A0B-B52DC24BA0CBQ35892164-C423777E-5DB1-4CD7-BD5F-BF47E2EAC0A0Q35892167-61E11694-AFA9-4651-AB85-2E3194389C0EQ35955904-50552A58-C7C0-4AE2-969C-BDD71897536FQ35959295-A5906E07-0736-4C39-B370-1979BD50260BQ36114610-934AD644-196D-4FC3-9540-92CB63DF2C2EQ36173814-DF7EBE84-9E0C-4D6A-9008-4E8A0CBF93C5Q36335258-5DADE459-197A-4D19-A0DE-A8A266217081Q36503060-88AD2004-5E1A-4AC1-AFB3-9195368C2150Q36587465-2CB3B940-1D6A-4195-A6DB-44798CD22143Q36616330-32E14D11-935B-4268-B7A5-1EBACDD47A44Q36716107-D1476D9E-1124-4886-A23E-D7366DD579FBQ36731358-99EB4309-B6EB-40C0-B987-A88B9FC1CEEDQ36800941-B88762A1-DFE8-42AA-BCE9-CDF5342BB46CQ36819603-84A7CC77-5904-4304-B05C-2203AD3C234DQ36917845-DBBB25D0-3284-46DD-9053-A5FF8F9E9655Q36929757-408240BB-477D-4A70-92EA-16C926111625Q36930296-D2BF7560-B488-40E7-BCFD-32091C26D1ABQ36970774-6911AA26-8E2D-42A3-A4A2-5E2D339F677BQ37004371-B7952B8D-47BF-4F55-B6AD-C0B2097C8669Q37008418-624D4373-AF0D-421B-829F-770006A3F0EAQ37012882-B0AA3988-E6CE-4274-82DC-C66E037DBC97
P2860
QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.
description
1964 nî lūn-bûn
@nan
1964 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1964 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1964年の論文
@ja
1964年論文
@yue
1964年論文
@zh-hant
1964年論文
@zh-hk
1964年論文
@zh-mo
1964年論文
@zh-tw
1964年论文
@wuu
name
QUINIDINE SYNCOPE. PAROXYSMAL ...... OF CHRONIC ATRIAL ARRHYTHMIAS.
@ast
QUINIDINE SYNCOPE. PAROXYSMAL ...... OF CHRONIC ATRIAL ARRHYTHMIAS.
@en
type
label
QUINIDINE SYNCOPE. PAROXYSMAL ...... OF CHRONIC ATRIAL ARRHYTHMIAS.
@ast
QUINIDINE SYNCOPE. PAROXYSMAL ...... OF CHRONIC ATRIAL ARRHYTHMIAS.
@en
prefLabel
QUINIDINE SYNCOPE. PAROXYSMAL ...... OF CHRONIC ATRIAL ARRHYTHMIAS.
@ast
QUINIDINE SYNCOPE. PAROXYSMAL ...... OF CHRONIC ATRIAL ARRHYTHMIAS.
@en
P356
P1433
P1476
QUINIDINE SYNCOPE. PAROXYSMAL ...... OF CHRONIC ATRIAL ARRHYTHMIAS.
@en
P2093
P356
10.1161/01.CIR.30.1.17
P407
P577
1964-07-01T00:00:00Z